arrow_back Back to App

Neuroscience Center of Excellence: Supporting Brain Disease Drug Development

The act authorizes the Secretary of Health and Human Services to establish a Neuroscience Center of Excellence within the FDA. The Center is tasked with coordinating collaborations and supporting the development of medical products for neurological and psychiatric diseases. The legislation includes programs regarding patient-focused drug development, natural history studies, and the impact of COVID-19 on these conditions.
Key points
Establishment of a Neuroscience Center of Excellence to support the development and approval of medical products for neurological diseases.
Implementation of a patient-focused drug development program, including the collection of patient experience data.
Examination of the impact of the COVID-19 pandemic on neurological and psychiatric diseases and strategies for rapid medical product development.
Authorization of $25 million for fiscal years 2023 through 2027 to carry out the Center's activities.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3427
Sponsor: Sen. Collins, Susan M. [R-ME]
Process start date: 2021-12-16
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Neuroscience Center of Excellence Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3427.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-12-16.

What are the main provisions?

Key points include:

  • Establishment of a Neuroscience Center of Excellence to support the development and approval of medical products for neurological diseases.
  • Implementation of a patient-focused drug development program, including the collection of patient experience data.
  • Examination of the impact of the COVID-19 pandemic on neurological and psychiatric diseases and strategies for rapid medical product development.
  • Authorization of $25 million for fiscal years 2023 through 2027 to carry out the Center's activities.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Collins, Susan M. [R-ME].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health